Synedgen Funding: How Much Did They Raise & Key Investors

How Much Did Synedgen Raise?
Funding & Key Investors

Synedgen has solidified its position within the biotechnology sector, securing a total capital infusion of $18.7M to advance its proprietary therapeutic pipeline. The company recently finalized a financing round totaling $0, marking a significant milestone in its trajectory toward commercializing regenerative solutions for complex gastrointestinal conditions. This latest injection of capital underscores investor confidence in the firm's ability to address critical unmet needs in mucosal barrier restoration.

The company's growth trajectory, characterized by a series of strategic debt and private equity placements, reflects a disciplined approach to scaling its research and development capabilities. By maintaining a focus on high-impact clinical outcomes, Synedgen continues to attract institutional interest, positioning itself as a key player in the evolving landscape of targeted pharmaceutical interventions.

What is Synedgen?

Synedgen

Manufacturing

Pharmaceuticals

Synedgen is a specialized biotechnology firm dedicated to the development of first-in-class therapeutics designed to restore mucosal barrier function. The company's primary focus lies in the treatment of gastrointestinal diseases, where its lead candidate, MIIST305, serves as a cornerstone for repairing mucosal injury and mitigating inflammation. By leveraging advanced regenerative medicine techniques, Synedgen aims to improve patient outcomes through orally delivered therapies that are supported by robust intellectual property and scalable GMP manufacturing processes. The firm operates at the intersection of clinical innovation and pharmaceutical scalability, catering to a market that demands precise, effective, and durable therapeutic solutions for chronic GI dysfunction.

How much funding has Synedgen raised?

Synedgen has raised a total of $18.7M across 6 funding rounds:

2014

Private Equity

$607K

2015

Private Equity

$3.5M

2016

Unspecified

$6M

Debt

$3M

2017

Debt

$3M

2020

Private Equity

$2.6M

Private Equity (2014): $607K, investors not publicly disclosed

Private Equity (2015): $3.5M, investors not publicly disclosed

Unspecified (2016): $6M, investors not publicly disclosed

Debt (2016): $3M featuring Undisclosed

Debt (2017): $3M backed by Undisclosed

Private Equity (2020): $2.6M, investors not publicly disclosed

Key Investors in Synedgen

Undisclosed Investors

What's next for Synedgen?

With the recent influx of capital, Synedgen is well-positioned to accelerate the clinical development of its lead therapeutic candidates. The strategic roadmap likely involves expanding the reach of MIIST305 through rigorous clinical trials and optimizing its manufacturing infrastructure to meet anticipated demand. As the company transitions from early-stage research to more advanced clinical phases, the focus will shift toward regulatory milestones and potential commercial partnerships. Investors and industry stakeholders will be monitoring the firm's ability to translate its regenerative technology into tangible market success, particularly as it navigates the complexities of the pharmaceutical regulatory environment and seeks to establish a dominant footprint in the GI therapeutic space.

See full Synedgen company page

See More Financial Insights